You just read:

Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference

News provided by

Eisai Inc.

Mar 06, 2019, 08:08 ET